Prager GW, Oehler L, Gerger A, et al. - In this first prospective, multicenter, non-interventional study, researchers sought to assess the tolerability and efficacy of nab-paclitaxel plus gemcitabine (nab-P/G) in younger (≤ 70 years) vs elderly (> 70 years) patients with metastatic pancreatic cancer (mPC) in the daily clinical routine. Eligible mPC patients were treated with nab-P/G and observed until disease progression or unacceptable toxicity. In total, 317 mPC patients (median age, 70 years) were recruited, of which 299, aged ≤ 70 (n = 162) and > 70 (n = 137) years, were eligible for analysis. Younger vs elderly patients equally benefited in terms of objective response rate, median progression-free survival and OS. Moreover, the median treatment duration, relative dose intensity, or reasons for treatment discontinuation were comparable. Fatigue (22.8% vs 13.0%) and decreased appetite (8.8% vs 1.2%) were more frequent in elderly patients vs younger ones. This prospective real-world analysis demonstrates the feasibility and tolerability of nab-P/G treatment and shows OS data similar to younger patients and elderly patients > 70 years of age.